{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:35:05Z","timestamp":1772447705895,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clon.2023.03.006","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T03:54:44Z","timestamp":1678852484000},"page":"e421-e433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review"],"prefix":"10.1016","volume":"35","author":[{"given":"S.L.","family":"Shear","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Shams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Weisberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.C.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clon.2023.03.006_bib1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.15585\/mmwr.mm7112e1","article-title":"Effectiveness of mRNA vaccination in preventing COVID-19 \u2013 associated invasive mechanical ventilation and death \u2014 United States, March 2021\u2013January 2022","volume":"71","author":"Tenforde","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.clon.2023.03.006_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","article-title":"Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clon.2023.03.006_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/s40249-021-00878-5","article-title":"Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Chen","year":"2021","journal-title":"Infect Dis Poverty"},{"issue":"50","key":"10.1016\/j.clon.2023.03.006_bib4","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.clon.2023.03.006_bib5","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2021.19499","article-title":"Association between mRNA vaccination and COVID-19 hospitalization and disease severity","volume":"326","author":"Tenforde","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clon.2023.03.006_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clon.2023.03.006_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.clon.2023.03.006_bib9","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.clon.2023.03.006_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.pedhc.2021.04.001","article-title":"Methodological analysis: randomized controlled trials for Pfizer and Moderna COVID-19 vaccines","volume":"35","author":"Hallas","year":"2021","journal-title":"J\u00a0Pediatr Health Care"},{"issue":"12","key":"10.1016\/j.clon.2023.03.006_bib11","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.clon.2023.03.006_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7830","key":"10.1016\/j.clon.2023.03.006_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.clon.2023.03.006_bib14","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10267","key":"10.1016\/j.clon.2023.03.006_bib15","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clon.2023.03.006_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.clon.2023.03.006_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clon.2023.03.006_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2021.09.030","article-title":"Predictors of poor seroconversion and adverse events to SARS-COV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment","volume":"159","author":"Buttiron Webber","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2023.03.006_bib48","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clon.2023.03.006_bib21","article-title":"Rayyan \u2013 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst\u00a0Rev"},{"issue":"6","key":"10.1016\/j.clon.2023.03.006_bib22","doi-asserted-by":"crossref","first-page":"P765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.03.006_bib23","series-title":"Validity and inter-rater reliability testing of quality assessment instruments. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021-I.)","author":"Hartling","year":"2012"},{"issue":"5","key":"10.1016\/j.clon.2023.03.006_bib24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ekir.2021.02.024","article-title":"Systematic review and meta-analysis of herpes zoster vaccine in patients with CKD","volume":"6","author":"Hamad","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1016\/j.clon.2023.03.006_bib2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1007\/s12149-021-01675-8","article-title":"Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients","volume":"35","author":"Advani","year":"2021","journal-title":"Ann Nucl Med"},{"issue":"5","key":"10.1016\/j.clon.2023.03.006_bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/RLU.0000000000003648","article-title":"Axillary lymph nodes hypermetabolism after BNT162b2 mRNA COVID-19 vaccination in cancer patients undergoing 18F-FDG PET\/CT: a cohort study","volume":"46","author":"Bernstine","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clon.2023.03.006_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2021.08.035","article-title":"COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy","volume":"157","author":"Cavanna","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clon.2023.03.006_bib36","doi-asserted-by":"crossref","first-page":"E345","DOI":"10.1148\/radiol.2021210886","article-title":"Prevalence of increased FDG PET\/CT axillary lymph node uptake beyond 6 weeks after mRNA COVID-19 vaccination","volume":"300","author":"Eshet","year":"2021","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.clon.2023.03.006_bib37","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.acra.2021.06.003","article-title":"COVID-19 vaccination induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases","volume":"28","author":"Faermann","year":"2021","journal-title":"Acad Radiol"},{"key":"10.1016\/j.clon.2023.03.006_bib38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.breast.2021.10.012","article-title":"COVID-19 vaccination in patients with breast cancer and gynecological malignancies: a German perspective","volume":"60","author":"Forster","year":"2021","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.clon.2023.03.006_bib25","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"issue":"33","key":"10.1016\/j.clon.2023.03.006_bib33","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.2217\/fon-2021-0597","article-title":"Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy","volume":"17","author":"Karacin","year":"2021","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.clon.2023.03.006_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028561","article-title":"Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: a retrospective single-center study","volume":"101","author":"Kian","year":"2022","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.clon.2023.03.006_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100272","article-title":"A\u00a0snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1\/PD-L1 inhibitors: a longitudinal cohort study","volume":"6","author":"Lasagna","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.clon.2023.03.006_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jnci\/djab174","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients","volume":"114","author":"Ligumsky","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.clon.2023.03.006_bib41","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.3390\/cancers13184621","article-title":"Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): a prospective cohort study of the Hellenic Cooperative Oncology Group","volume":"13","author":"Linardou","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clon.2023.03.006_bib42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41391-021-00455-9","article-title":"Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients","volume":"25","author":"Liontos","year":"2022","journal-title":"Prostate Cancer Prostat Dis"},{"issue":"1","key":"10.1016\/j.clon.2023.03.006_bib43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jtho.2021.08.761","article-title":"Axillary lymphadenopathy after coronavirus disease 2019 vaccinations in patients with thoracic malignancy: incidence, predisposing factors, and imaging characteristics","volume":"17","author":"Nishino","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2023.03.006_bib44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejca.2021.06.023","article-title":"Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: a monocentre study","volume":"154","author":"Placke","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2023.03.006_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2021.06.002","article-title":"The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience","volume":"154","author":"Revon-Riviere","year":"2021","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.clon.2023.03.006_bib47","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S1470-2045(21)00427-7","article-title":"Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy","volume":"22","author":"Scoccianti","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clon.2023.03.006_bib49","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.clon.2023.03.006_bib26","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1158\/2159-8290.CD-21-1072","article-title":"Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors","volume":"11","author":"Waldhorn","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clon.2023.03.006_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.breast.2021.08.017","article-title":"SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4\/6 inhibitors","volume":"60","author":"Zagouri","year":"2021","journal-title":"Breast"},{"issue":"10241","key":"10.1016\/j.clon.2023.03.006_bib27","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"10241","key":"10.1016\/j.clon.2023.03.006_bib28","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.clon.2023.03.006_bib7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2023.03.006_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2022.04.036","article-title":"Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer","volume":"171","author":"Pinato","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clon.2023.03.006_bib30","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","article-title":"Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.03.006_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.06.038","article-title":"COVID-19: third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: a population-based study","volume":"175","author":"Lee","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523001139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523001139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:52:42Z","timestamp":1760543562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655523001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0936655523001139"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2023.03.006","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2023.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}